首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4334篇
  免费   452篇
  国内免费   100篇
耳鼻咽喉   46篇
儿科学   211篇
妇产科学   149篇
基础医学   529篇
口腔科学   70篇
临床医学   555篇
内科学   1268篇
皮肤病学   34篇
神经病学   215篇
特种医学   174篇
外国民族医学   1篇
外科学   840篇
综合类   80篇
一般理论   2篇
预防医学   236篇
眼科学   57篇
药学   188篇
肿瘤学   231篇
  2019年   52篇
  2018年   50篇
  2017年   65篇
  2016年   53篇
  2015年   44篇
  2014年   88篇
  2013年   133篇
  2012年   122篇
  2011年   139篇
  2010年   100篇
  2009年   84篇
  2008年   130篇
  2007年   182篇
  2006年   152篇
  2005年   181篇
  2004年   128篇
  2003年   114篇
  2002年   105篇
  2001年   130篇
  2000年   113篇
  1999年   104篇
  1998年   79篇
  1997年   69篇
  1996年   49篇
  1995年   54篇
  1994年   63篇
  1993年   65篇
  1992年   87篇
  1991年   88篇
  1990年   99篇
  1989年   115篇
  1988年   111篇
  1987年   82篇
  1986年   113篇
  1985年   106篇
  1984年   78篇
  1983年   80篇
  1982年   49篇
  1981年   46篇
  1980年   48篇
  1979年   67篇
  1978年   69篇
  1977年   55篇
  1976年   53篇
  1975年   67篇
  1974年   78篇
  1973年   67篇
  1972年   62篇
  1970年   46篇
  1967年   48篇
排序方式: 共有4886条查询结果,搜索用时 109 毫秒
1.
There is a sharp difference in how one views TCR structure–function–behaviour dependent on whether its recognition of major histocompatibility complex‐encoded restriction elements (R) is germline selected or somatically generated. The generally accepted or Standard model is built on the assumption that recognition of R is by the V regions of the αβ TCR, which is not driven by allele specificity, whereas the competing model posits that recognition of R is allele‐specific. The establishing of allele‐specific recognition of R by the TCR would rule out the Standard model and clear the road to a consideration of a competing construct, the Tritope model. Here, the case for allele‐specific recognition (germline selected) is detailed making it obvious that the Standard model is untenable.  相似文献   
2.
3.
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding.  相似文献   
4.
Mortality and morbid events are insensitive guides to the efficacy and safety of interventions in chronic cardiovascular disease (CVD). To enhance the ability to find new and effective long-term treatments, especially for the early stages of CVD, a revised strategy for clinical trials should emphasize efficacy on disease progression while monitoring symptoms and quality of life as guides to clinical benefit. Mortality, which is uncommon except in acute or advanced disease, provides at best a crude guide to net efficacy and safety. It must be monitored to support demonstrated efficacy on disease progression without adverse safety effects. This revised approach, made possible by our enhanced ability to monitor the progression of disease, should make it possible to study earlier disease and to improve cardiovascular health while reducing health care costs.  相似文献   
5.
顺铂聚乳酸微球的药物释放特性及肝动脉栓塞研究   总被引:5,自引:0,他引:5  
对顺铂聚乳酸微球进行了体外药物释放和家犬肝动脉栓塞研究。该微球粒径范围为50~200μm,平均粒径为115.76±35.94μm,顺铂含量为37.16%(W/W);体外药物释放机制符合Higuchi方程;肝动脉栓塞后8h,肝组织顺铂浓度高达21.55±12.18μg/g,明显高于肝动脉灌注顺铂组:3.16±0.09μg/g(P<0.05);肝动脉栓塞组的顺铂血浓峰值、各取血点浓度及曲线下面积AUC皆低于肝动脉灌注顺铂组。可望达到提高栓塞部位的药物疗效,降低全身毒副反应的作用。  相似文献   
6.
7.
Primary tuberculous pathology in nasolpolypi is a rare condition. A case of bilateral ethmoidal polypi with tubercular lesion diagnosed on histopathologlcal examination is being reported and the available relevant literature has been reviewed.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号